Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 63.2%

Neg 63.2% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $24 to $22.